Researchers from the University of Minnesota’s Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that — for the first time — makes the production of human muscle cells from stem cells efficient and effective.
The research, published May 4 inCell Stem Cell, outlines the strategy for the development of a rapidly dividing population of skeletal myogenic progenitor cells (muscle-forming cells) derived from induced pluripotent (iPS) cells. iPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.
This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.
CONTINUED at Science Daily.